From 1 September 2026, the prescriber accreditation requirement for hepatitis B medicines under the PBS Section 100 (s100) Highly Specialised Drugs Program will be removed. As a result, all medical and authorised nurse practitioners will be able to prescribe hepatitis B antiviral treatment without additional specialist accreditation. ASHM is currently updating its website, education and resources to reflect this change.

Find out more

Back

Interpreting The Liverpool Hep Interactions Checker

First published:

March 2025

Last published:

2019

Overview

This 1-page flow-chart developed by the University of Liverpool in collaboration with ASHM and INHSU outlines simple steps to follow after identifying potential drug-drug interactions involving hepatitis C direct acting antiviral (DAA) regimens.

Primary care providers can confidently determine when and how to proceed with DAA treatment after consulting this resource. The drug-drug interactions checker website can be found here.

This resource was published more than two years ago. Some information may be outdated or may not reflect current clinical evidence and guidelines. Please contact us with any queries.